Emerging PEGylated non-biologic drugs
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, E.J. | - |
dc.contributor.author | Choi, J. | - |
dc.contributor.author | Lee, K.C. | - |
dc.contributor.author | Na, D.H. | - |
dc.date.available | 2019-08-13T05:57:52Z | - |
dc.date.issued | 2019-04 | - |
dc.identifier.issn | 1472-8214 | - |
dc.identifier.issn | 1744-7623 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/33101 | - |
dc.description.abstract | Introduction: PEGylation is a well-established technology for improving the therapeutic value of drugs by attaching polyethylene glycol (PEG). The first PEGylated enzyme products appeared on the market in the early 1990s; currently, more than 18 PEGylated products have been approved by Food and Drug Administration, which encompass various classes of drug molecules, such as enzymes, interferons, granulocyte colony-stimulating factors, hormones, antibody fragments, coagulation factors, oligonucleotide aptamers, synthetic peptides, and small organic molecules. Areas covered: While PEGylated products mainly comprise biologic drugs, such as recombinant proteins and enzymes, non-biologic drugs have recently emerged as a target for PEGylation. This review focuses on the recent development of PEGylated non-biologic drugs, such as small organic molecules, synthetic peptides, and aptamers. Expert opinion: Several PEGylated versions of anti-cancer drugs, opioid agonists, glucagon-like peptide-1 receptor agonists, and oligonucleotide aptamers are in active development stage, and it is likely that they will have a dramatic impact on the market. Although some safety concerns about PEG in clinical trials have been recently issued, PEGylation is still a commercially attractive proposition as a half-life extension technology for long-acting drug development. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. | - |
dc.format.extent | 13 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Taylor and Francis Ltd | - |
dc.title | Emerging PEGylated non-biologic drugs | - |
dc.type | Article | - |
dc.identifier.doi | 10.1080/14728214.2019.1604684 | - |
dc.identifier.bibliographicCitation | Expert Opinion on Emerging Drugs, v.24, no.2, pp 107 - 119 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000485074500004 | - |
dc.identifier.scopusid | 2-s2.0-85068752524 | - |
dc.citation.endPage | 119 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 107 | - |
dc.citation.title | Expert Opinion on Emerging Drugs | - |
dc.citation.volume | 24 | - |
dc.type.docType | Review | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | aptamers | - |
dc.subject.keywordAuthor | non-biologic drugs | - |
dc.subject.keywordAuthor | PEGylation | - |
dc.subject.keywordAuthor | small organic molecules | - |
dc.subject.keywordAuthor | synthetic peptides | - |
dc.subject.keywordPlus | ETIRINOTECAN PEGOL NKTR-102 | - |
dc.subject.keywordPlus | SITE-SPECIFIC PEGYLATION | - |
dc.subject.keywordPlus | POLYETHYLENE-GLYCOL PEG | - |
dc.subject.keywordPlus | CHRONIC KIDNEY-DISEASE | - |
dc.subject.keywordPlus | COLLAGEN PENTAPEPTIDES | - |
dc.subject.keywordPlus | SALMON-CALCITONIN | - |
dc.subject.keywordPlus | DOSE-ESCALATION | - |
dc.subject.keywordPlus | 2 SCHEDULES | - |
dc.subject.keywordPlus | PHASE-I | - |
dc.subject.keywordPlus | POLYMER | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.